Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database.
BRAF
Cancer
biomarkers
colon
kinase
melanoma
Journal
Experimental biology and medicine (Maywood, N.J.)
ISSN: 1535-3699
Titre abrégé: Exp Biol Med (Maywood)
Pays: England
ID NLM: 100973463
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
pubmed:
7
10
2020
medline:
24
4
2021
entrez:
6
10
2020
Statut:
ppublish
Résumé
These data represent the largest aggregation of BRAF mutations within a single clinical database to our knowledge. The relative proportions of both BRAF V600 mutations and non-V600 mutations are informative in all cancers and by malignancy, and can serve as a definitive gold-standard for BRAF mutation cancer incidence by malignancy. The rate of BRAF mutation in human cancer in a real-world large database is lower than previously reported likely representing testing more broadly across tumor types. The relative percentages of Class II and Class III BRAF mutations are higher than previously reported, representing almost 35% of BRAF mutations in cancer. These findings provide support for the development of effective treatments for non-V600 BRAF mutations in cancer.
Identifiants
pubmed: 33019809
doi: 10.1177/1535370220959657
pmc: PMC7797994
doi:
Substances chimiques
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
31-39Références
Nat Rev Mol Cell Biol. 2015 May;16(5):281-98
pubmed: 25907612
Br J Cancer. 2013 May 28;108(10):2164-71
pubmed: 23579220
EMBO J. 2012 May 30;31(11):2629-47
pubmed: 22510884
Cancer Discov. 2016 Feb;6(2):154-65
pubmed: 26566875
Nature. 2011 Nov 23;480(7377):387-90
pubmed: 22113612
N Engl J Med. 2011 Jun 30;364(26):2507-16
pubmed: 21639808
Clin Cancer Res. 2018 Dec 15;24(24):6107-6109
pubmed: 30042206
Nature. 2017 Aug 10;548(7666):234-238
pubmed: 28783719
Oncologist. 2018 Jun;23(6):740-745
pubmed: 29438093
Arch Pathol Lab Med. 2012 Nov;136(11):1385-91
pubmed: 22332713
N Engl J Med. 2009 Jul 2;361(1):98-9
pubmed: 19571295
Eur J Cancer. 2017 Jul;79:176-184
pubmed: 28501764
Case Rep Oncol. 2016 Sep 22;9(3):543-546
pubmed: 27790118
N Engl J Med. 2012 Jul 12;367(2):107-14
pubmed: 22663011
N Engl J Med. 2019 Aug 15;381(7):626-636
pubmed: 31166680
Cancer Cell. 2014 Sep 8;26(3):402-413
pubmed: 25155755
PLoS One. 2012;7(4):e35309
pubmed: 22536370
J Clin Oncol. 2015 Dec 1;33(34):4032-8
pubmed: 26460303
Cancer Res. 2017 Dec 1;77(23):6513-6523
pubmed: 28951457
J Clin Pathol. 2013 May;66(5):441-5
pubmed: 23463675
Lancet Oncol. 2018 Oct;19(10):1315-1327
pubmed: 30219628
Diagn Mol Pathol. 2012 Mar;21(1):1-8
pubmed: 22306669
N Engl J Med. 2019 Oct 24;381(17):1632-1643
pubmed: 31566309
Clin Cancer Res. 2017 Sep 15;23(18):5339-5348
pubmed: 28611198
Lancet Oncol. 2016 Sep;17(9):1248-60
pubmed: 27480103
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
Pathology. 2012 Jun;44(4):357-9
pubmed: 22614711
Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
J Clin Oncol. 2011 Apr 1;29(10):1239-46
pubmed: 21343559
Int J Cancer. 2019 Nov 1;145(9):2488-2495
pubmed: 30963570
Mol Cell. 2005 Dec 22;20(6):963-9
pubmed: 16364920
Anticancer Agents Med Chem. 2011 Mar;11(3):285-95
pubmed: 21426297
Melanoma Res. 2017 Dec;27(6):585-590
pubmed: 29076950
J Clin Oncol. 2019 Nov 20;37(33):3142-3151
pubmed: 31580757
Exp Hematol Oncol. 2017 Mar 21;6:6
pubmed: 28344857
PLoS One. 2012;7(10):e47054
pubmed: 23056577
Cell. 2004 Mar 19;116(6):855-67
pubmed: 15035987
Nat Struct Mol Biol. 2015 Jan;22(1):37-43
pubmed: 25437913
Oncogene. 2018 Jun;37(24):3183-3199
pubmed: 29540830
Cancer Res. 2012 Feb 1;72(3):779-89
pubmed: 22180495
Int J Hematol. 2013 Mar;97(3):313-23
pubmed: 23456262
Ann Oncol. 2017 Jul 1;28(7):1631-1639
pubmed: 28475671
Lancet Oncol. 2016 Jul;17(7):984-993
pubmed: 27283860
Ann Surg. 2007 Sep;246(3):466-70; discussion 470-1
pubmed: 17717450
Lancet Oncol. 2017 Apr;18(4):464-472
pubmed: 28268064
Lancet Oncol. 2016 May;17(5):642-50
pubmed: 27080216
J Mol Diagn. 2013 Mar;15(2):220-6
pubmed: 23273605
J Mol Diagn. 2011 Sep;13(5):504-13
pubmed: 21726664
J Transl Med. 2010 Jul 14;8:67
pubmed: 20630094
Clin Cancer Res. 2012 Jun 15;18(12):3242-9
pubmed: 22535154
Melanoma Res. 2014 Oct;24(5):504-8
pubmed: 24933606
Cancer. 2013 Feb 1;119(3):548-554
pubmed: 22930283
Nat Med. 2019 Feb;25(2):284-291
pubmed: 30559419
Cancer Cell. 2015 Sep 14;28(3):370-83
pubmed: 26343582
Pathology. 2008 Apr;40(3):295-8
pubmed: 18428050
Lancet Oncol. 2017 Oct;18(10):1307-1316
pubmed: 28919011
Blood. 2012 Jan 5;119(1):192-5
pubmed: 22028477
Cancer Res. 2002 Dec 1;62(23):6997-7000
pubmed: 12460918
Lancet. 2012 Jul 28;380(9839):358-65
pubmed: 22735384
N Engl J Med. 2014 Nov 13;371(20):1877-88
pubmed: 25265492
Neuro Oncol. 2017 Jun 1;19(6):774-785
pubmed: 28082416